Product Description
Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus (RSV). It belongs to a group of medicines known as immunizing agents. This medicine works by giving your body antibodies to protect it against RSV infection. (Sourced from: https://www.mayoclinic.org/drugs-supplements/palivizumab-intramuscular-route/description/drg-20065268)
Mechanisms of Action: FP Inhibitor,RNA Replication Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intramuscular,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Chile, Colombia, Czech Republic, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Malaysia, Mexico, New Zealand, Norway, Peru, Puerto Rico, Russia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Respiratory Syncytial Virus Infections
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031210664 | P3 |
Recruiting |
Respiratory Syncytial Virus Infections |
2026-07-01 |
|
| MK-1654-007 | P3 |
Unknown Status |
Respiratory Syncytial Virus Infections |
2026-04-27 |
|
| MK-1654-007 | P3 |
Active, not recruiting |
Respiratory Syncytial Virus Infections |
2025-04-29 |
|
| 2020-005996-11 | P3 |
Active, not recruiting |
Respiratory Syncytial Virus Infections |
2025-02-13 |